Rybrevant drug combo demonstrates durable PFS in second-line EGFR-mutated NSCLC in CHRYSALIS-2 cohort

Immunotherapy + radiation show promise for bladder preservation in localized MIBC, phase II study shows

Patients with localized muscle-invasive bladder cancer who received radiation plus the immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical study published in Clinical Cancer Research, a journal of the AACR.

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.

CAR T therapy shows durable responses in large B-cell lymphoma

Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.

Scientists identify dysfunctional B cells as a new cancer immunotherapy target

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood—known as the tertiary lymphoid structure—where they become dysfunctional when in close contact with tumors.